Below is the information acquired on ASTELLAS PHARMA INC, which is not yet included in our research perimeter.

To request an evaluation of this company and its inclusion in the OpenCorporation Ranking or if you have additional, different and more updated data than what is published in this OpenCorporation company card, please write to info@opencorporation.org so that our team may take it in account.

Last update 31 March 2022

Description of economic activities

Manufacture of pharmaceutical preparations (NACE2 2120)

This company is engaged in manufacturing, marketing and importing/exporting of pharmaceuticals and related products. The company was formed through the merger of Yamanouchi Pharmaceutical Co., Ltd. and Fujisawa Pharmaceutical Co., Ltd in April 2005. It conducts business from its registered head office which is strategically located in Tokyo, Japan. The company contributes to improving the health of people around the world through the provision of innovative and reliable pharmaceutical products. The company is targeting urology, immunology and inflammation, diabetes, central nervous system and pain, infectious diseases including viruses and cancer. Its major research laboratories in Japan are located in Tsukuba and Osaka and development bases are integrated in Tokyo. Clinical development is the primary focus of overseas operations, with a North American center in Illinois, and a European center in the Netherlands, with additional facilities in Germany. With one of the largest sales forces in Japan, it is further strengthening its marketing organization to consolidate its number one position in both quality and quantity in the domestic ethical drug market. It aims to establish competitive advantages in selected therapeutic areas, carrying a wide spectrum of products with sizable sales in each field. In Japan, mainstay products areas include: urology (Vesicare and Harnal), transplants and immunology (Prograf, Protopic and Intal), cardiovascular (Lipitor, Micardis, Dorner), gastrointestinal organs (Gaster), infection diseases (Fubguard, Targosid and Cefzon), and psychiatry (Myslee, Luvox and Seroquel). It is cementing its presence as an R&D driven global pharmaceutical company by further expanding its R&D, production, and marketing organizations in the U.S., the world's largest pharmaceutical market, as well as in major countries in Europe and Asia. In the US market, the company is achieving sustained growth in the transplants, cardiovascular, dermatology, infectious diseases and urology fields. In Europe, it also carries out R&D, manufacturing, and marketing. Its European headquarters in United Kingdom oversees the whole of Europe with its nineteen sales subsidiaries. In fast-growing Asian markets (China, Southeast Asia), it has already established marketing and production functions in China and marketing functions in Korea and Taiwan.
  • ASTELLAS PHARMA INC

  • Japan (JP)
  • Company type: Corporate
  • Parent company: N/A
  • Chief Executive Officer (CEO): Mr Yoshihiko Hatanaka
  • CEO Total remuneration: N/A
  • Website: www.astellas.com

Financial data

Number of employees

N/A
15,455
15,883
16,243

Revenue 1

N/A
10
11
10

EBIT 1

N/A
1
2
2

EBITDA 1

N/A
3
3
3

1 numbers are in millions

  • RepRisk Indicator (last month):  18

Social dialog

  • Transnational Corporate Agreement (TCA): N/A
  • Global Framework Agreement (GFA): N/A
  • Societas Europaea (SE): N/A
  • Bangladesh Accord: N/A

European Works Councils

  • EWC: N/A

Standards and certifications

Global Reporting Initiative certification

  • Global Reporting Initiative standards: N/A
  • Global Reporting Initiative GRI G4: N/A

Other company declarations

Policies

  • Training policy: N/A
  • Policy to protect the right to health and safety in the workplaces where the company operates: N/A
  • Policy to protect the right to health and safety in the workplaces in the supply chain: N/A
  • Diversity policy: N/A

Universal declarations

Declarations and treaties recognised by the country where the company has its registered office

  • Universal Declaration of Human Rights:
  • European Convention on Human Rights (ECHR):
  • Charter of Fundamental Rights of CDFL Workers (Strasbourg Charter 1989):
  • Charter of Fundamental Rights of the European Union EU CFR (Nice Charter 2000):
  • Treaty on the Functioning of the European Union TFEU:
  • Registered office in an OECD country:
  • ILO C029 - Forced Labour Convention, 1930 (No. 29):
  • ILO C087 - Freedom of Association and Protection of the Right to Organise Convention, 1948 (No. 87):
  • ILO C098 - Right to Organise and Collective Bargaining Convention, 1949 (No. 98):
  • ILO C100 - Equal Remuneration Convention, 1951 (No. 100):
  • ILO C105 - Abolition of Forced Labour Convention, 1957 (No. 105):
  • ILO C111 - Discrimination (Employment and Occupation) Convention, 1958 (No. 111):
  • ILO C138 - Minimum Age Convention, 1973 (No. 138):
  • ILO C182 - Worst Forms of Child Labour Convention, 1999 (No. 182):

Directives applied in the company offices in EU 27

  • D. 80/987/EEC: N/A
  • D. 89/391/EEC: N/A
  • D. 98/59/EC: N/A
  • D. 2000/43/EC: N/A
  • D. 2000/78/EC: N/A
  • D. 2001/23/EC: N/A
  • Council D. 2001/86/EC: N/A
  • D. 2002/14/EC: N/A
  • D. 2002/73/EC: N/A
  • Council D. 2003/72/EC: N/A
  • EP and Council D. 2005/56/EC: N/A
  • D. 2009/38/EC: N/A
  • D. 2004/25/EC: N/A
  • D. 2011/35/EU: N/A

Presence in main rankings

  • Global 100 Most Sustainable Corporations:
  • Global CSR Rep Trak 100: N/A
  • BrandZ Top 100 Most Valuable US Brands: N/A
  • The Worlds Best Multinational Workplaces: N/A
  • The Gartner Supply Chain Top 25: N/A
  • The Worlds Most Innovative Companies: N/A
  • The Diversity Inc Top 50 Companies: N/A
  • Best Global Websites: N/A
  • Green Ranking Global Top 500: N/A
  • Green Ranking Global Top 100: N/A

Reference trade unions